Patients must not have clinical evidence of central nervous system involvement by lymphoma; if performed, any laboratory or radiographic tests performed to assess central nervous system (CNS) involvement must be negative

Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement

Presence of central nervous system (CNS) involvement requiring active treatment

Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization

Known central nervous system (CNS) involvement

Patients with a known central nervous system (CNS) involvement of lymphoma are not eligible (CNS staging not required)

Leukemia with active central nervous system (CNS) involvement

Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy

Subjects with known active or history of CNS involvement by malignancy

Known central nervous system involvement by PTCL

Active central nervous system (CNS) involvement by leukemia

Current or past history of central nervous system (CNS) disease, or CNS involvement by MM

Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis

Known CNS involvement at diagnosis

Patients with evidence of current central nervous system leukemic involvement

Symptomatic central nervous system (CNS) involvement which are neurologically unstable or requiring increasing doses of steroids to control.

Central nervous system involvement

Presence of active/uncontrolled central nervous system involvement

Central nervous system (CNS) involvement

Patients with any central nervous system involvement or CTCL.

Central nervous system involvement

Patients with known central nervous system (CNS) involvement of lymphoma are not eligible

Evidence of leukemic meningitis or other central nervous system (CNS) involvement by leukemia

Active, uncontrolled central nervous system (CNS) involvement by lymphoma

Active involvement of the central nervous system (CNS) by lymphoma; work-up for CNS involvement at diagnosis will be directed as per the treating physician and will depend on specific clinical circumstances (no brain imaging or lumbar puncture is required by this protocol)

Clinical evidence suggestive of central nervous system (CNS) involvement with MDS unless a lumbar puncture confirms the absence of leukemic blasts in the cerebrospinal fluid (CSF)

Patients must not have known central nervous system (CNS) involvement of lymphoma

Central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells

Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 70

Patients with known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement

Subject has confirmed central nervous system (CNS) involvement by DLBCL. Subjects at risk for CNS involvement per Investigator assessment must receive prophylaxis. For subjects at risk, or with any neurological symptoms, testing for CNS involvement is required at Screening.

Has clinical signs of central nervous system (CNS) involvement of MM.

Active CNS involvement

Known active central nervous system (CNS) involvement by lymphoma should be excluded from this clinical trial

Central nervous system involvement by lymphoma, including leptomeningeal involvement

Central Nervous System (CNS) involvement with multiple myeloma defined as csf positivity for plasma cells or a parenchymal CNS plasmacytoma

EXCLUSION - INFUSION: Patients with central nervous system involvement

Known central nervous system (CNS) involvement by lymphoma

Myeloma-related central nervous system involvement

Central nervous system involvement

Active central nervous system (CNS) involvement with leukemia

Active CNS involvement of their malignancy.

Central nervous system involvement with lymphoma at any time in the patient’s history; intrathecal prophylaxis during induction is allowed as long as active disease has not been identified

Active central nervous system (CNS) involvement by malignancy, except in cases of virus-associated malignancies with CNS involvement in which case the patient may benefit from the transplant to control the malignancy

Suggestive central nervous system involvement with leukemia

Central nervous system involvement

CNS metastatic involvement

Symptomatic central nervous system involvement.

Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy

Central nervous system (CNS) involvement by lymphoma/leukemia

Central nervous system involvement.

Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)

Patients with active known central nervous system (CNS) involvement of CLL or lymphoma; (patients with history of CNS CLL or lymphoma now in remission are eligible for the trial)

Known central nervous system (CNS) involvement by malignancy

Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation

Known central nervous system (CNS) involvement by lymphoma; patients at high risk for secondary CNS involvement but without neurologic symptoms suspected to be due to lymphoma are allowed to be enrolled and receive intrathecal chemotherapy including but not limited to methotrexate, cytarabine and glucocorticoids; patients who are enrolled and subsequently identified to have pathologic confirmation of CNS involvement by lymphoma may be continued on study at the discretion of the principal investigator

Any active central nervous system or meningeal involvement

Known central nervous system (CNS) involvement with CLL or T-LGL

Evidence of lymphoma outside of the central nervous system\r\n* Ocular involvement will not exclude

Known central nervous system involvement

Known, current central nervous system disease involvement or untreated brain metastases

Active, uncontrolled central nervous system (CNS) leukemia involvement

Known clinically active central nervous system (CNS) involvement; prior evidence of CNS involvement successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment and there are no neurological signs of potential CNS involvement

History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid [CSF] within one week of enrollment) and have no evidence of new sites of CNS activity

Known clinically active CNS involvement.

Subject has known active central nervous system (CNS) involvement from AML

Active central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural disease

Known active involvement of the central nervous system by lymphoma or leukemia

Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 90 days prior to registration.

Prior central nervous system (CNS) involvement by tumor cells;

Patients with active central nervous system (CNS) involvement with lymphoma are not eligible

Documented history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, whole body magnetic resonance imaging (MRI) and lumbar cytology are required

Known central nervous system (CNS) involvement

Participant has known active central nervous system (CNS) involvement with AML.

Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement

Active central nervous system (CNS) involvement by malignancy

Patients with history of central nervous system (CNS) involvement

Active central nervous system (CNS) metastases and/or leptomeningeal involvement

History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid (CSF) within one week of enrollment) and have no evidence of new sites of CNS activity

Known central nervous system (CNS) involvement

Active central nervous system (CNS) involvement of leukemia (lumbar puncture not required to rule out CNS involvement if not suspected)

Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement

Known active central nervous system (CNS) involvement

Has either clinical evidence of or history of central nervous system involvement by AML.

Known active central nervous system (CNS) involvement by MM

The toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknown

Subject has known active central nervous system (CNS) involvement with AML

Active or previous central nervous system leukemia involvement

Central nervous system involvement with disease under study (myeloma), or concurrent AL amyloidosis or plasma cell leukemia

Patients who have known central nervous system involvement with multiple myeloma will be excluded from this clinical trial

Known central nervous system (CNS) involvement by lymphoma

Evidence of active central nervous system (CNS) involvement

Active or previous central nervous system leukemia involvement

known active central nervous system (CNS) involvement by malignancy.

Central nervous system involvement with MM (by clinical symptoms and signs).

Central nervous system (CNS) involvement, including lymphomatous meningitis

Active central nervous system (CNS) or testicular involvement by leukemia

Has known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement; subjects with prior CNS involvement by lymphoma must have remission of the CNS component of the lymphoma; these subjects must have a baseline magnetic resonance imaging (MRI) during screening without evidence of new or enlarging brain lesions and must not have any new or progressive neurologic symptoms

Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma

Prior central nervous system (CNS) involvement by tumor cells

No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet ALL of the following to be eligible:

History of or known active central nervous system (CNS) involvement with AML

Active central nervous system (CNS) involvement or leptomeningeal involvement

Prior or active central nervous system (CNS) involvement by myeloma (eg leptomeningeal disease); screening for this, for example, by lumbar puncture, is only required if suspicious symptoms or radiographic findings are present

Participant has known Central Nervous System (CNS) involvement with AML.

A history of AML related central nervous system (CNS) involvement is allowed if most recent cerebrospinal fluid (CSF) analysis is negative at least 2 weeks prior to study treatment

Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven)

Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement

Active involvement of the central nervous system with malignancy

History of plasma cell leukemia or multiple myeloma (MM) central nervous system (CNS) involvement

Active, untreated central nervous system (CNS) involvement

No known history or suspicion of central nervous system involvement by lymphoma

Participants with central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL

Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)

Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory

Known central nervous system (CNS) involvement

Patients with active central nervous system (CNS) involvement with lymphoma are not eligible

Subjects must not have known central nervous system involvement by disease (parenchymal, meningeal or cerebrospinal fluid)

Known cytopathologically confirmed central nervous system (CNS) infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)

Central nervous system metastases, including leptomeningeal involvement

Central nervous system (CNS) involvement

Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months

Central nervous system (CNS) involvement by lymphoma

CNS involvement with malignancy.

Known central nervous system involvement with the disease under study

Primary central nervous system involvement only

Patients with known central nervous system involvement should be excluded from this clinical trial

Central nervous system (CNS) or meningeal involvement, or cord compression by the lymphoma; history of CNS lymphoma

Have prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma; screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms are present

Central nervous system (CNS) involvement

History of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvement

Has known active central nervous system involvement of the malignancy.

Central nervous system (CNS) involvement by lymphoma (clinically or cytologically confirmed)

Patients with current central nervous system (CNS) involvement by malignancy (either by imaging or cerebrospinal fluid involvement or biopsy-proven)

Patients with known or suspected central nervous system involvement of lymphoma.

All patients with central nervous system involvement with lymphoma

Known lymphomatous involvement of the central nervous system

History of central nervous system multiple myeloma involvement

Patients with known central nervous system (CNS) involvement

Known brain metastases or central nervous system (CNS) involvement

Suspected AML-related central nervous system involvement; a lumbar puncture (LP) is not required to exclude central nervous system (CNS) disease

Subjects with known central nervous system involvement with multiple myeloma

Active involvement of the central nervous system with malignancy

Subjects must not have prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma; screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms are present

Has known clinically active central nervous system (CNS) involvement

Known central nervous system (CNS) tumor involvement

History of plasma cell leukemia or MM central nervous system (CNS) involvement

History of CNS involvement by MM

Active central nervous system (CNS) involvement within the previous 2 months

Active central nervous system (CNS) involvement of the underlying malignancy

Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration

Known active central nervous system involvement

Central nervous system (CNS) involvement

Central nervous system involvement of the disease under study

Central nervous system involvement

Known lymphomatous involvement of the central nervous system

Known central nervous system involvement

Presence of central nervous system involvement of leukemia or a history of primary central nervous system leukemia.

Active central nervous system (CNS) neoplastic involvement

Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment

Patients must not have active central nervous system involvement

Primary central nervous system lymphoma or known intracranial involvement

Central nervous system (CNS) involvement within 3 months

Patient must have no current or prior history of central nervous system (CNS) involvement

Skin involvement.

Active involvement of the central nervous system with malignancy; this can be documented as a normal neurological exam and/or a negative cerebrospinal fluid (CSF) analysis

Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement

Known active central nervous system (CNS) involvement

No evidence of extramedullary leukemia, such as central nervous system (CNS) or soft tissue involvement

Patient with active central nervous system (CNS) involvement

Participants with known central nervous system (CNS) involvement with leukemia or who are receiving intrathecal chemotherapy that is either prophylactic or therapeutic; history of CNS involvement that has been completely treated (no longer receiving intrathecal chemotherapy) will be allowed

Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)

Patients with known central nervous system (CNS) involvement

Central nervous system or meningeal involvement

Active involvement of the central nervous system with malignancy

Active involvement of the central nervous system with malignancy

Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy

Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning (day -6)

Patients with known central nervous system (CNS) involvement by leukemia

Known leptomeningeal involvement.

Central nervous system involvement.

Patients with active central nervous system (CNS) involvement by malignant cells

Has active central nervous system (CNS) involvement (documented by radiologic lesions and/or malignant cells in the cerebrospinal fluid [CSF]).

History of or known active central nervous system (CNS) involvement or leptomeningeal involvement

Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)

Active central nervous system involvement with AML.

Has central nervous system (CNS) involvement of leukemia or a history of CNS leukemia

Known central nervous system or meningeal involvement (in the absence of symptoms, investigation into central nervous system involvement is not required)

Known active involvement of the central nervous system by lymphoma or leukemia

Known central nervous system involvement by multiple myeloma

History of plasma cell leukemia or central nervous system (CNS) involvement

Patients with known central nervous system involvement should be excluded from this clinical trial

Central nervous system involvement (Bing-Neel syndrome)

Known involvement of central nervous system

Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy; diagnostic lumbar puncture is to be performed

Central nervous system involvement by lymphoma, including leptomeningeal involvement

Active central nervous system (CNS) disease – if a history of AML related CNS involvement, screening cerebrospinal fluid (CSF) analysis must be negative

Patient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease.

Known central nervous system (CNS) involvement with lymphoma.

Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy

Patient has distant metastatic disease, including central nervous system (CNS) tumor involvement

Clinical evidence of central nervous system involvement.

Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:

Symptomatic central nervous system (CNS) involvement by AML

Untreated central nervous system (CNS) involvement

Known central nervous system involvement or brain metastases

Active central nervous system (CNS) involvement or leptomeningeal metastases involvement

Known active central nervous system (CNS) involvement with AML at study entry

Active central nervous system involvement by leukemia

Patients with suspected central nervous system (CNS) involvement should undergo lumbar puncture; those with documented CNS involvement will be excluded

Active central nervous system involvement

Uncontrolled central nervous system (CNS) disease involvement

Patients with a history of central nervous system involvement by CLL or who have prolymphocytic leukemia (PLL)

AML central nervous system (CNS) involvement

Patients with documented central nervous system involvement of AML

Has known clinically active central nervous system (CNS) involvement OR history of resolved CNS involvement by multiple myeloma

Active central nervous system involvement by malignancy

Central nervous system involvement; a lumbar puncture does not need to be performed unless there is clinical suspicion of leptomeningeal disease

With central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy, cranial irradiation or both prior to initiating conditioning (day -6)

Documented current central nervous system involvement by multiple myeloma

Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy

Patients with history of central nervous system (CNS) involvement or active CNS involvement by malignancy

Patients must have no known central nervous system (CNS) involvement by lymphoma

Central nervous system (CNS) involvement by lymphoma including parenchymal brain or spinal cord lymphoma or known presence of leptomeningeal disease prior to registration

Patients with metabolic storage diseases who have severe central nervous system (CNS) involvement of disease, defined as intelligence quotient (IQ) score < 70

Active central nervous system (CNS) involvement by malignancy

Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma

History of or current, central nervous system involvement with AML.

Patients must not have clinical evidence of central nervous system (CNS) involvement by lymphoma            \r\n* Any laboratory or radiographic tests performed to assess CNS involvement must be negative and must be performed within 42 days prior to registration

Known clinically active central nervous system involvement.

Subject has known active central nervous system involvement with AML.

Active Central Nervous System (CNS) involvement by malignancy

Has known clinically active central nervous system (CNS) involvement

Have active leukemic involvement of the central nervous system (CNS).

Central nervous system (CNS) involvement by lymphoma/leukemia

Patients with controlled asymptomatic central nervous system involvement are allowed.

Patients who have symptomatic central nervous system (CNS) involvement are not eligible

Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease

Active central nervous system (CNS) involvement of disease

CNS lymphoma involvement

Patients must not have active involvement of the central nervous system (CNS) with MM (by clinical evaluation); patients with documentation of, or clinical signs or symptoms consistent with, CNS involvement of MM must have a lumbar puncture that is negative for CNS involvement of MM; the lumbar puncture must be completed within 14 days prior to registration; patients with no previous history of documented CNS involvement and with no clinical signs or symptoms consistent with CNS involvement are not required to have completed a lumbar puncture prior to registration; note that monitoring of CNS involvement and treatment with intrathecal therapy is recommended during protocol treatment

Active AML involvement of the central nervous system (CNS) with disease refractory to intrathecal chemotherapy

Central nervous system (CNS) involvement.

Patients with documented central nervous system (CNS) involvement

Subject who has central nervous system (CNS) or meningeal involvement by lymphoma.

Subjects with Central Nervous System involvement with multiple myeloma

Central nervous system involvement of the CLL

Active uncontrolled central nervous system involvement

Presence or history of central nervous system involvement by lymphoma.

Patient must have no known central nervous system (CNS) involvement

Patients with known central nervous system involvement at the time of study entry will be excluded from this clinical trial

AML patients with known, active leptomeningeal/central nervous system (CNS) involvement

Known, current central nervous system disease involvement or untreated brain metastases

Participants with active central nervous system (CNS) involvement are excluded; patients with suspected CNS disease should be worked up appropriately prior to enrollment

No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted

Primary or secondary Central Nervous System involvement by lymphoma.

Myeloma-related central nervous system involvement

Known central nervous system (CNS) involvement by malignancy

Patients with leukemic involvement of the central nervous system

Patient has active or history of central nervous system (CNS) disease or meningeal involvement

Central nervous system involvement (based on clinical assessment)

Known central nervous system (CNS) involvement

Symptomatic central nervous system (CNS) lymphoma involvement

Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration

Known clinically active central nervous system involvement

Known active involvement of the central nervous system by lymphoma or leukemia

Active central nervous system (CNS) involvement with leukemia

Central nervous system involvement

Known lymphomatous involvement of the central nervous system.

Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required)

Participant has known active central nervous system (CNS) involvement with AML.

Active central nervous system involvement by lymphoma

Known central nervous system involvement

Central nervous system involvement.

Known involvement of the central nervous system by WM.

Subjects with known or suspected central nervous system (CNS) involvement are not eligible

Patients with known central nervous system (CNS) involvement are excluded from this clinical trial

Central nervous system (CNS) involvement by CLL.

Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.

Central nervous system involvement

Research participants with known brain metastases (central nervous system [CNS] involvement either parenchymal or leptomeningeal involvement)

Patients with a history of central nervous system involvement by lymphoma

Has evidence of uncontrolled central nervous system (CNS) involvement (previous radiation and off steroids is acceptable)

Central nervous system (CNS) involvement by lymphoma

Phase II: Patients with untreated, relapsed or refractory T-cell lymphoma, including patients with central nervous system (CNS) involvement or lymphomatous meningitis are allowed on study

Active involvement of the central nervous system with malignancy

History of central nervous system (CNS) involvement by myeloma

Known central nervous system (CNS) involvement of lymphoma

Known central nervous system (CNS) involvement

Central nervous system (CNS) involvement of the patient's lymphoma

Patients with active central nervous system (CNS) involvement with lymphoma should be excluded from this clinical trial

Presence of confirmed distant metastases, including central nervous system and vertebral or meningeal involvement

Central nervous system disease involvement

Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation

Central nervous system involvement

Patients with a history of central nervous system (CNS) leukemia are eligible if they are not symptomatic from current CNS involvement\r\n* If there is CNS involvement that is known prior to enrollment or identified subsequently, it will be treated accordingly

Known Central nervous system involvement, brain metastasis

Known central nervous system or meningeal involvement (in the absence of symptoms investigation into central nervous system involvement is not required); patients with human T-cell lymphotropic virus type 1 (HTLV1) adult T-cell leukemia/lymphoma (ATLL) and controlled central nervous system (CNS) or meningeal involvement may be enrolled after discussion with the Memorial Sloan Kettering (MSK) principal investigator

Patients with central nervous system (CNS) involvement

Known active central nervous system involvement

Central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy and/or cranial radiation prior to initiation of conditioning; diagnostic lumbar puncture is to be performed per protocol

Untreated central nervous system (CNS) involvement; (treated CNS involvement is permitted only if the patient is not currently on steroid therapy or has remained on a stable, unchanged dose of steroid for >= 2 weeks)

Histolo-cytologically proven PMLBL (phase II)\r\n* PMLBL without central nervous system (CNS) involvement\r\n* Slides will be reviewed by the national pathology panel, but review is not mandatory before registration

Known central nervous system (CNS) involvement

Central nervous system involvement.

Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast magnetic resonance imaging (MRI) for at least 3 months prior to study entry

Patient with active central nervous system (CNS) involvement with lymphoid malignancy

Presence or history of central nervous system involvement by lymphoma

Known central nervous system (CNS) involvement by lymphoma.

Known central nervous system involvement by leukemia

Known cytopathologically confirmed central nervous system (CNS) infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)

Patients with central nervous system involvement by APL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice

Uncontrolled central nervous system (CNS) involvement with disease

Known active CNS involvement

Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy

No known central nervous system involvement by myeloma.

Known central nervous system (CNS) lymphoma involvement

Evidence of AML central nervous system (CNS) involvement

Disease-related central nervous system involvement

Known CNS involvement of indolent lymphoma

Documented current central nervous system involvement by leukemia or lymphoma

Central nervous system (CNS) involvement.

Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy

CLL central nervous system involvement

Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy and/or standard cranial-spinal radiotherapy

No known involvement of central nervous system by lymphoma

Active diagnosis of central nervous system (CNS) involvement with CLL

Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy

Evidence of sanctuary site involvement by disease, e.g., central nervous system, ocular, testicular involvement

Active central nervous system (CNS) involvement by malignancy (defined as CNS-3 per National Comprehensive Cancer Network [NCCN] guidelines)

Patient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded.

Known central nervous system lymphoma or ALL with central nervous system (CNS) involvement

Central nervous system (CNS) involvement of DLBCL

Active involvement of the central nervous system with malignancy

Current central nervous system (CNS) involvement by lymphoma

Untreated central nervous system involvement

Known central nervous system (CNS) involvement

CNS or leptomeningeal involvement of lymphoma

Active central nervous system (CNS) disease involvement

Known central nervous system involvement

Clinically active central nervous system (CNS) cancer involvement. Imaging to exclude CNS involvement not required.

Known central nervous system involvement

Active central nervous system involvement by malignancy; central nervous system disease that has been treated into remission is permitted; a chart note of the clinician’s impression of lack of central nervous system (CNS) involvement is acceptable

Known active and uncontrolled central nervous system (CNS) involvement of leukemia (a lumbar puncture does not need to be performed as a part of screening)

Symptomatic central nervous system (CNS) involvement

Known active cerebral/meningeal involvement with lymphoma; asymptomatic patients with previously treated and resolved central nervous system (CNS) lymphoma involvement are permitted

Patients with untreated central nervous system involvement by AML should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; this is an uncommon situation in AML and therefore a lumbar puncture for cerebrospinal fluid (CSF) sampling or magnetic resonance imaging (MRI) imaging are NOT necessary to rule out central nervous system (CNS) involvement in the absence of clinical suspicion by the treating physician

Patients must have relapsed or refractory cluster of differentiation (CD) 20+ lymphoid malignancies with either documented central nervous system (CNS) involvement or peripheral nerve infiltration

Had evidence of active central nervous system (CNS) involvement

Active central nervous system (CNS) lymphoma/leukemia - Patients with prior CNS involvement are eligible provided that it has been treated and is in remission

Documented current central nervous system involvement

Symptomatic central nervous system involvement

Symptomatic central nervous system (CNS) involvement

Known uncontrolled central nervous system involvement

Lymphoma involvement of the central nervous system

Active or symptomatic central nervous system (CNS) disease or epidural involvement

For Part B only: Known leukemic involvement or clinical symptoms of leukemic involvement of the central nervous system

Evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration

Symptomatic, steroid-requiring or progressive central nervous system (CNS) involvement

Active involvement of the Central Nervous System (CNS).

Clinically uncontrolled central nervous system (CNS) involvement

Central nervous system involvement

Patients with central nervous system (CNS) metastatic involvement.

Clinically uncontrolled central nervous system (CNS) involvement

Patients with a history of central nervous system involvement by lymphoma

Patients with known central nervous system involvement.

Patients must not have clinical evidence of central nervous system involvement by lymphoma, since proposed treatment would not be able to address it adequately; any laboratory (e.g., lactate dehydrogenase [LDH]) or radiographic tests performed to access central nervous system (CNS) involvement must be negative and must be performed within 42 days prior to registration

Clinical evidence of CNS involvement by lymphoma

Known, active (symptomatic) involvement of the central nervous system by leukemia.

Known central nervous system (CNS) involvement

Active central nervous system (CNS) involvement of their malignancy.

Known leukemic involvement of the central nervous system.

Documented current central nervous system involvement by leukemia or lymphoma

Central nervous system involvement

No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted

Has central nervous system involvement

Central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells

Known Central Nervous System (CNS) involvement by lymphoma.

Presence of central nervous system (CNS) involvement with Hodgkin lymphoma

Uncontrolled central nervous system (CNS) involvement by tumor cells

Active central nervous system (CNS) involvement by malignancy

Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma

Prior central nervous system (CNS) involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment.

History of central nervous system involvement of lymphoma;

All patients with active central nervous system involvement with lymphoma

Known evidence of active cerebral/meningeal CLL; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration

History of central nervous system (CNS) involvement

Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy

Known presence of central nervous system (CNS) involvement by lymphoma

Known central nervous system (CNS) involvement

No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted

Patients with known central nervous system (CNS) involvement

Participants with known central nervous system (CNS) involvement of lymphoma

Patient must not have active central nervous system (CNS) involvement

INCLUSION CRITERIA FOR PATIENTS: No central nervous system involvement of disease

Active central nervous system (CNS) involvement by malignant cells

EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment)

Active central nervous system (CNS) involvement by malignant cells

Patients with active central nervous system involvement

Symptomatic central nervous system involvement.

History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma

Known central nervous system involvement by multiple myeloma

Active central nervous system (CNS) involvement by malignant cells

Active central nervous system (CNS) involvement by malignant cells

Clinical suspicion of active central nervous system (CNS) involvement by leukemia

Known central nervous system (CNS) involvement

Known central nervous system (CNS) involvement by AML

Has presence of central nervous system (CNS) involvement of leukemia or a history of CNS leukemia

Patients must not have known central nervous system (CNS) involvement

Patients with known central nervous system (CNS) involvement

Known central nervous system (CNS) involvement of lymphoma (CNS staging not required)

Clinical signs of central nervous system (CNS) involvement of MM.

Known uncontrolled central nervous system involvement by malignant disease